Natera (NASDAQ:NTRA) Stock Acquired Rep. Josh Gottheimer

Key Points

• Representative Josh Gottheimer purchased shares of Natera, Inc. for between $1,001 and $15,000 on August 22nd, as disclosed in a filing on September 5th.
• Natera's recent quarterly earnings report showed a revenue of $546.60 million, exceeding estimates, but it posted a loss per share of ($0.74), missing expectations.
• Multiple analysts have maintained a "buy" rating on Natera, with price targets ranging from $170.00 to $220.00, reflecting a generally positive outlook on the stock.

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Natera, Inc. NASDAQ: NTRA. In a filing disclosed on September 05th, the Representative disclosed that they had bought between $1,001 and $15,000 in Natera stock on August 22nd. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Sysmex OTCMKTS: SSMXY on 8/21/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/12/2025.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 8/12/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/1/2025.
• Sold $1,001 - $15,000 in shares of Walmart NYSE: WMT on 7/28/2025.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 7/25/2025.
• Sold $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/18/2025.
• Sold $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 7/16/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 7/14/2025.

Natera Stock Down 0.4%

Natera stock opened at $167.39 on Tuesday. Natera, Inc. has a 12-month low of $114.62 and a 12-month high of $183.00. The firm's fifty day moving average is $154.32 and its 200 day moving average is $153.72. The company has a market capitalization of $22.97 billion, a PE ratio of -87.64 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the firm posted ($0.30) EPS. The business's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the firm's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00. Following the transaction, the insider directly owned 120,859 shares in the company, valued at $20,137,526.58. This trade represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Natera

A number of large investors have recently modified their holdings of NTRA. LRI Investments LLC bought a new position in shares of Natera in the fourth quarter valued at approximately $29,000. Bank of Jackson Hole Trust purchased a new stake in Natera in the first quarter valued at approximately $29,000. Rakuten Securities Inc. raised its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC purchased a new stake in Natera in the first quarter valued at approximately $32,000. Finally, TCTC Holdings LLC raised its stake in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NTRA shares. Stephens reiterated an "overweight" rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Piper Sandler reiterated an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target for the company in a report on Monday, July 28th. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of "Buy" and an average price target of $194.00.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.